Physician profile
Boyd Sprenkle
NPI 1306808159
$2,201.15
in general payments reported to CMS, 2019-2025
14 companies · $298 in 2025
The $298 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $608 · 2020: $16.24 · 2021: $31.63 · 2022: $208 · 2023: $265 · 2024: $775 · 2025: $298.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,338.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,337.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $846.10 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals Lp | $835.33 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Genentech USA, INC. | $78.31 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.28 | 2019-2022 | |
| Grifols USA, LLC | $56.82 | 2019 | |
| Mallinckrodt Hospital Products INC. | $56.20 | 2022-2023 | Acthar |
| Verona Pharma, INC. | $47.37 | 2025 | Ohtuvayre |
| Baxter Healthcare | $36.41 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $35.15 | 2019 | |
| Genzyme Corporation | $35.10 | 2019 | |
| Amgen INC. | $33.69 | 2024 | Tezspire |
| Abbvie INC. | $26.72 | 2024 | |
| Mallinckrodt Enterprises LLC | $24.43 | 2019 | |
| Insmed, INC. | $16.24 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Boyd Sprenkle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.